R&D expense · 2020–2025
Monte Rosa Therapeutics R&D expense
$142M+16.4% · FY2025
Monte Rosa Therapeutics (GLUE) reported $142M in R&D expense for fiscal 2025, +16.4% year on year.
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2020–2025 compound annual growth +42.6%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Monte Rosa Therapeutics R&D expense |url=https://companiesranked.com/en/company/monte-rosa-therapeutics/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Monte Rosa Therapeutics R&D expense. CompaniesRanked. https://companiesranked.com/en/company/monte-rosa-therapeutics/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-monte-rosa-therapeutics-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Monte Rosa Therapeutics R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/monte-rosa-therapeutics/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-109360 · March 17, 2026
{{cite web |title=Monte Rosa Therapeutics R&D expense — 10-K (0001193125-26-109360) |url=https://www.sec.gov/Archives/edgar/data/1826457/000119312526109360/glue-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-17}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.